HSBC Australia Faces A$35M Penalty Over Scam Protection Failures 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
Microsoft Taps AWS to Support GitHub Amid AI Coding Boom 
Carro Expands Into Australia With Acquisition of Used-Car Platform CarPlace 
GM and Lockheed Martin Partner to Strengthen U.S. Defense Manufacturing Capacity 
Jio IPO Filing Nears as Reliance Targets $4 Billion Market Debut 
SK Hynix Shares Hit Record High After Shipping Next-Generation HBM4E AI Memory Samples 
Google Gemini Co-Lead Noam Shazeer Leaves for OpenAI Amid AI Talent Race 
Meta Seeks Legal Shield From Child-Harm Lawsuits Amid KOSA Talks 
G7 Explores AI Access Deal With U.S. Amid Anthropic Restrictions 
SpaceX Surpasses Amazon in Market Value as Post-IPO Rally Accelerates 
Saudi Aramco Explores Sulphur Business Stake Sale to Raise Billions 
Trump Says Anthropic No Longer Seen as National Security Threat 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
Trump Administration Delays DeepSeek and CXMT Trade Blacklist Designations Amid U.S.-China Tensions 
Qantas Unveils Wellness-Focused Nonstop Sydney-London Flights to Reduce Jet Lag 
THE WOODLANDS, Texas, Jan. 11, 2016 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced that the United States Court of Appeals for the Federal Circuit summarily affirmed the ruling of the United States District Court for the Southern District of Texas in favor of the Company in the Company’s motions for summary judgment that Dr. Fisch failed to present sufficient evidence to be added as a co-inventor of U.S. Patent Nos. 7,737,185 and 7,759,360, covering therapeutic uses of enclomiphene, and that equitable estoppel barred Dr. Fisch's counterclaims seeking to be added as a co-inventor of the patents at issue, in its lawsuit against Dr. Harry Fisch.
About Repros Therapeutics Inc.®
Repros Therapeutics focuses on the development of small molecule drugs for major unmet medical needs that treat male and female reproductive disorders.
For more information, please visit the Company’s website at http://www.reprosrx.com.
CONTACT: Investor Relations: Thomas Hoffmann The Trout Group (646) 378-2931 [email protected]
